



PRESS RELEASE

28 April 2005

deltaDOT APPOINTS ANTHONY BAXTER AS CEO

London, UK, 28th April, 2005 deltaDOT, an innovator in real time biomolecular screening, today announces the appointment of Anthony Baxter as CEO, with immediate effect.

Anthony Baxter has over 21 years experience in management and research within the pharmaceutical and biotech industry. Prior to deltaDot, Mr Baxter has held, CEO, CSO and board level positions in a number of companies. Most recently he was CEO of Argenta Discovery where he founded and led the company from concept to becoming a fully operational leader in its field. Mr Baxter has been instrumental in the development of marketed drugs such as Lotroned, Abacavir and Lamivudine and in the discovery of clinical development candidates for a number of companies including pharmaceutical giant, GSK.

On his appointment, Mr Baxter said, "deltaDot has massive potential and an extremely innovative and exciting range of products. I look forward to leading the company at this time as the true value of its technology and products can now be realised".

- ENDS -

Notes to Editors

deltaDOT is creating new biotools that will significantly enhance productivity in pharmaceutical and biotechnology research. The Company's first product is a High Performance Capillary Electrophoresis (HPCE) system that uses deltaDOT's proprietary Label Free Intrinsic Imaging (LFII) to accurately analyse candidate drug compounds, either nucleic acid or proteins, with enhanced speed, resolution and improved running costs. deltaDOT's technology has major competitive advantages over competing Capillary Electrophoresis instruments that offer lower sensitivity, resolution, quantification and power.

The Company is based in London and derives its original intellectual property and scientific expertise from Imperial College. At the forefront of biotechnology and bioinformatics, deltaDOT is working at the interface of innovatory materials, computation, microstructures and pattern recognition. The combination of nuclear physics detection technology, algorithms and analytical instrumentation offered by deltaDOT has created a new paradigm in biotechnology - label free intrinsic imaging - which allows direct monitoring of unlabelled biomolecules at unrivalled resolution with unique sensitivity.

For further details visit: www.deltadot.com

deltaDOT
Anthony Baxter, CEO
Tel +44-(0)-207-594-1003
a.baxter@deltadot.com

De Facto Communications
Maria Payne/Richard Anderson
Tel + 44 207 940 1000
m.payne@defacto.com/r.anderson@defacto.com

